// App-Quantinova.ai

AB0811 : DEMOGRAPHIC, TREATMENT AND DISEASE CHARACTERISTICS OF PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING TOFACITINIB IN THE UNITED STATES, FRANCE, GERMANY, ITALY, SPAIN AND THE UNITED KINGDOM

Researchers

Presenter

  • A. Ogdie

Principal Investigators

  • L. Schmerold

  • W. Tillett

  • R. Germino

  • J. C. Cappelleri

  • P. Young

Medical Centers

  • University of Pennsylvania, Philadelphia, United States of America

  • SmartAnalyst Inc, New York, United States of America

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Pfizer, Inc, New York, NY, United States of America

  • Pfizer, Inc, Groton, CT, United States of America

  • Pfizer Inc., Collegeville, United States

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved